(b).

Sex	Dose (mg/kg)	WBC (109/L)	LYM (%)	NEUT (%)	MONO (%)	EO (%)	BASO (%)
Male	1000	7.81 ± 1.09	74.6 ± 5.3	18.7 ± 4.8	4.90 ± 0.82	1.79 ± 0.47	0.02 ± 0.06
	500	8.19 ± 1.37	73.5 ± 4.8	19.9 ± 4.2	5.05 ± 0.83	1.55 ± 0.60	0.04 ± 0.08
	250	8.72 ± 1.74	74.3 ± 5.3	19.2 ± 5.6	4.89 ± 0.63	1.61 ± 0.47	0.02 ± 0.06
	Control	8.49 ± 1.38	73.8 ± 4.4	19.2 ± 4.6	5.14 ± 0.62	1.89 ± 0.45	0.04 ± 0.08
Female	1000	7.74 ± 1.19	75.3 ± 3.4	18.2 ± 3.9	4.40 ± 0.55	2.05 ± 0.52	0.02 ± 0.06
	500	8.19 ± 0.86	76.1 ± 5.2	17.1 ± 5.0	5.02 ± 0.78	1.77 ± 0.80	0.02 ± 0.06
	250	8.06 ± 1.35	74.4 ± 5.2	18.5 ± 5.1	4.97 ± 0.62	2.11 ± 0.54	0.03 ± 0.09
	Control	7.76 ± 1.20	75.5 ± 4.6	17.8 ± 4.5	4.82 ± 0.52	1.82 ± 0.60	0.04 ± 0.08

Note: The values represent the mean ± standard deviation of 10 rats. HGB: hemoglobin concentration; RBC: red blood cell count; PLT: platelet count; HCT: hematocrit; PT: prothrombin time; APTT: activated partial thromboplastin time; WBC: white blood cell count; LYM: percent of lymphocytes; NEUT: percent of neutrophils; MONO: percent of monocytes; EO: percent of eosinophils; BASO: percent of basophils. The values of the treatment groups did not differ statistically from the control according to one-way ANOVA at p < 0.05.